<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="49221">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02465450</url>
  </required_header>
  <id_info>
    <org_study_id>JBT101-CF-001</org_study_id>
    <nct_id>NCT02465450</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 in Cystic Fibrosis</brief_title>
  <official_title>A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corbus Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corbus Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and
      efficacy of JBT-101 in adult subjects with cystic fibrosis (CF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An interventional, double-blind, randomized, placebo-control design will be used to test
      safety, tolerability, pharmacokinetics, and efficacy of JBT-101 in 70 subjects ≥ 18 and &lt; 65
      years of age with documented cystic fibrosis. There will up a screening period of up to 28
      days, 84 days treatment period, and 28 days follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment emergent adverse events from baseline at Day 113</measure>
    <time_frame>112 days, with 84 days treatment and 28 days follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in JBT-101 plasma concentrations from baseline at Day 85</measure>
    <time_frame>84 days treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lung function from baseline at Day 85</measure>
    <time_frame>84 days treatment period</time_frame>
    <description>Forced expiratory volume in one second (FEV1) and lung clearance index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported outcomes from baseline at Day 85</measure>
    <time_frame>84 days treatment period</time_frame>
    <description>Cystic Fibrosis Questionnaire Revised - Respiratory Symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolipidomic profile from baseline at Day 85</measure>
    <time_frame>84 days treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood biomarkers of disease activity from baseline to Day 85</measure>
    <time_frame>84 days treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sputum biomarkers of disease activity from baseline to Day 85</measure>
    <time_frame>84 days treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood biomarkers of inflammation from baseline to Day 85</measure>
    <time_frame>84 days treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sputum microbiota from baseline to Day 85</measure>
    <time_frame>84 days treatment period</time_frame>
    <description>Total bacterial load, bacterial genera, and relative abundance of each genera in sputum</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>JBT101 1 mg/20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JBT-101 1 mg once a day on Days 1-28, then JBT-101 20 mg every morning on Days 29-84 and placebo every evening on Days 29-84</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JBT-101 1 mg/20 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JBT-101 1 mg once a day on Days 1-28, then JBT-101 20 mg twice a day on Days 29-84</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JBT-101 5 mg/20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JBT-101 5 mg once a day on Days 1-28, then JBT-101 20 mg every morning on Days 29-84 and placebo every evening on Days 29-84</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JBT-101 5 mg/20 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JBT-101 5 mg once a day on Days 1-28, then JBT-101 20 mg twice a day on Days 29-84</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JBT-101 0 mg/20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo once a day on Days 1-28, then JBT-101 20 mg every morning on Days 29-84 and placebo every evening on Days 29-84</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JBT-101 0 mg/20 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo once a day on Days 1-28, then JBT-101 20 mg twice a day on Days 29-84</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once a day on Days 1-28, then placebo twice a day on Days 29-84</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JBT-101</intervention_name>
    <description>Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84.</description>
    <arm_group_label>JBT101 1 mg/20 mg</arm_group_label>
    <arm_group_label>JBT-101 1 mg/20 mg bid</arm_group_label>
    <arm_group_label>JBT-101 5 mg/20 mg</arm_group_label>
    <arm_group_label>JBT-101 5 mg/20 mg bid</arm_group_label>
    <arm_group_label>JBT-101 0 mg/20 mg</arm_group_label>
    <arm_group_label>JBT-101 0 mg/20 mg bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo once a day on Days 1-28, placebo q pm on Days 29-84 (with JBT-101 20 mg q am), or placebo bid on Days 29-84.</description>
    <arm_group_label>JBT101 1 mg/20 mg</arm_group_label>
    <arm_group_label>JBT-101 5 mg/20 mg</arm_group_label>
    <arm_group_label>JBT-101 0 mg/20 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documentation of a CF diagnosis as evidenced by 1 or more clinical features
             consistent with the CF phenotype and 1 or more of the following criteria:

               1. Sweat chloride equal to or greater than 60 mEq/L by quantitative pilocarpine
                  iontophoresis test;

               2. Two well-characterized mutations in the CFTR gene

          -  FEV1 ≥ 40% predicted corrected

          -  Stable treatment of CF for 14 days before Visit 1

        Exclusion Criteria:

          -  Severe or unstable CF, such as:

               1. Intravenous antibiotic treatment within 14 days before Visit 1

               2. Treatment with any corticosteroids &gt; 10 mg per day or &gt; 20 mg every other day
                  oral prednisone or equivalent within 14 days before Visit 1

          -  Any one of the following values for laboratory tests at Screening:

               1. A positive pregnancy test (or at Visit 1);

               2. Hemoglobin &lt; 10 g/dL

               3. Neutrophils &lt; 1.0 x 10~9/L

               4. Platelets &lt; 75 x 10~9/L

               5. Creatinine clearance &lt; 50 ml/min according to modified Cockcroft-Gault equation

               6. Serum transaminases &gt; 2.5 x upper normal limit

               7. Total bilirubin ≥ 1.5 x upper limit of normal

          -  Any other condition that, in the opinion of the Principal Investigator, is clinically
             significant and may put the subject at greater safety risk, influence response to
             study product, or interfere with study assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Chmiel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center, Cleveland, OH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J S Elborn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queens University, Belfast, Northern Ireland, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center/Miller Children's and Women's Hospital</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Robert-Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore LIJ Health System</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital Clinical Care Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution Hôpital Pasteur</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Perharidy</name>
      <address>
        <city>Roscoff</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiane Herzog CF-Zentrum Frankfurt am Main</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hesse</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNI Essen Abt.Pneumologie</name>
      <address>
        <city>Essen</city>
        <state>North Rhine-Westphalia</state>
        <zip>45127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOUI di Verona - Ospedale Borgo Trento UOC Fibrosi Cistica</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Dziecięcy Polanki im. Macieja Płażyńskiego w Gdańsku Spółka z o.o. Poradnia Leczenia Mukowiscydozy</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-308</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorium Cassia-Villa Medica s.c</name>
      <address>
        <city>Rabka Zdrój</city>
        <zip>34-700</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Podkarpacki Ośrodek Pulmunologii i Alergologii</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-612</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Gruźlicy i Chorób Płuc I Klinika Chorób Płuc</name>
      <address>
        <city>Warszawa</city>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 21, 2016</lastchanged_date>
  <firstreceived_date>June 4, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
